Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 10 studies | 26% ± 10% | |
fibroblast | 10 studies | 19% ± 3% | |
oligodendrocyte | 10 studies | 27% ± 9% | |
astrocyte | 9 studies | 30% ± 12% | |
oligodendrocyte precursor cell | 8 studies | 28% ± 11% | |
adipocyte | 7 studies | 24% ± 6% | |
glutamatergic neuron | 6 studies | 46% ± 17% | |
GABAergic neuron | 6 studies | 40% ± 16% | |
interneuron | 6 studies | 42% ± 19% | |
neuron | 5 studies | 28% ± 12% | |
epithelial cell | 5 studies | 36% ± 10% | |
pericyte | 5 studies | 19% ± 4% | |
retinal cone cell | 4 studies | 22% ± 3% | |
cardiac muscle cell | 4 studies | 17% ± 1% | |
basal cell | 4 studies | 26% ± 8% | |
dendritic cell | 4 studies | 33% ± 17% | |
glial cell | 3 studies | 23% ± 8% | |
microglial cell | 3 studies | 20% ± 3% | |
B cell | 3 studies | 31% ± 16% | |
plasma cell | 3 studies | 23% ± 7% | |
ciliated cell | 3 studies | 22% ± 5% | |
Mueller cell | 3 studies | 18% ± 1% | |
retina horizontal cell | 3 studies | 16% ± 1% | |
chondrocyte | 3 studies | 18% ± 3% | |
neural progenitor cell | 3 studies | 32% ± 14% | |
ependymal cell | 3 studies | 30% ± 13% | |
connective tissue cell | 3 studies | 18% ± 1% | |
transit amplifying cell | 3 studies | 26% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1314.94 | 1445 / 1445 | 100% | 14.92 | 183 / 183 |
brain | 100% | 802.86 | 2640 / 2642 | 100% | 15.00 | 705 / 705 |
breast | 100% | 1203.14 | 459 / 459 | 100% | 13.43 | 1114 / 1118 |
lung | 100% | 981.60 | 576 / 578 | 100% | 13.74 | 1154 / 1155 |
prostate | 100% | 1011.69 | 245 / 245 | 99% | 9.15 | 499 / 502 |
ovary | 100% | 818.61 | 180 / 180 | 99% | 10.33 | 426 / 430 |
stomach | 100% | 699.55 | 359 / 359 | 99% | 10.66 | 283 / 286 |
uterus | 100% | 1240.98 | 170 / 170 | 99% | 15.59 | 454 / 459 |
intestine | 100% | 1237.93 | 966 / 966 | 99% | 10.42 | 521 / 527 |
bladder | 100% | 1161.10 | 21 / 21 | 99% | 12.84 | 498 / 504 |
thymus | 100% | 879.92 | 652 / 653 | 99% | 10.07 | 598 / 605 |
skin | 100% | 1332.90 | 1809 / 1809 | 97% | 20.12 | 457 / 472 |
pancreas | 96% | 447.27 | 315 / 328 | 99% | 8.74 | 176 / 178 |
kidney | 100% | 795.98 | 89 / 89 | 94% | 8.14 | 847 / 901 |
adrenal gland | 100% | 1078.28 | 258 / 258 | 91% | 7.07 | 210 / 230 |
liver | 100% | 548.55 | 226 / 226 | 90% | 6.37 | 366 / 406 |
adipose | 100% | 1271.37 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1166.87 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 8.07 | 29 / 29 |
muscle | 100% | 1603.52 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 670.37 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.60 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.03 | 1 / 1 |
heart | 100% | 1165.38 | 857 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 80% | 8.49 | 64 / 80 |
peripheral blood | 57% | 518.51 | 531 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000045 | Biological process | autophagosome assembly |
GO_0061025 | Biological process | membrane fusion |
GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
GO_0031396 | Biological process | regulation of protein ubiquitination |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0007030 | Biological process | Golgi organization |
GO_0045861 | Biological process | negative regulation of proteolysis |
GO_1904293 | Biological process | negative regulation of ERAD pathway |
GO_0031468 | Biological process | nuclear membrane reassembly |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0005801 | Cellular component | cis-Golgi network |
GO_0043204 | Cellular component | perikaryon |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0030425 | Cellular component | dendrite |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0033130 | Molecular function | acetylcholine receptor binding |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
Gene name | UBXN2A |
Protein name | UBX domain-containing protein 2A (UBX domain-containing protein 4) |
Synonyms | UBXD4 |
Description | FUNCTION: Acts to repress the ubiquitination and subsequent endoplasmic reticulum-associated degradation of CHRNA3 by the STUB1-VCP-UBXN2A complex in cortical neurons . Also acts to promote the translocation of CHRNA3 to the plasma membrane and subsequently increases plasma membrane acetylcholine-gated ion-channel activation (By similarity). Plays a role in the inhibition of STUB1-mediated TP53 degradation, via its interaction with HSPA9 which acts to inhibit TP53 binding to HSPA9 . Positively mediates the ubiquitination and proteosomal degradation of RICTOR, may thereby act as a negative regulator of the mTORC2 pathway . . |
Accessions | P68543 ENST00000309033.5 [P68543-1] ENST00000404924.5 [P68543-1] |